Funding for this research was provided by:
Horizon 2020 (720694)
Received: 12 January 2021
Accepted: 11 March 2021
First Online: 20 March 2021
: The study was approved by the Medical Ethical Testing Committee of the Erasmus Medical Centre (MEC-2018-1636).Informed consent was obtained from all individual participants included in the study.
: Patients signed informed consent regarding publishing their data.
: Disclosure of conflict of interest: Dr. Visser reports grants from European Union’s Horizon 2020 research and innovation program, during the conduct of the study; Dr. Louapre reports grants and personal fees from Biogen, personal fees from Novartis, personal fees from Merck, personal fees from Roche, personal fees from Teva, personal fees from Sanofi, outside the submitted work; Dr. Uyl-de Groot has nothing to disclose.; Dr. Redekop reports grants from European Union’s Horizon 2020 research and innovation program, during the conduct of the study